MRI lesions: A surrogate for relapses in multiple sclerosis?

The Lancet Neurology

Volumn 12, Issue 7, 2013, Pages 628-630

  Rudick, Richard A ^a   Cutter, Gary ^b  

^a LERNER RESEARCH INSTITUTE   (United States)

^b UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BETA INTERFERON; GLATIRAMER;

BRAIN ATROPHY; CONTROLLED CLINICAL TRIAL (TOPIC); DRUG EFFICACY; HUMAN; LETTER; MULTIPLE SCLEROSIS; NUCLEAR MAGNETIC RESONANCE IMAGING; PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; RECURRENCE RISK; WHITE MATTER LESION;

HUMANS; MAGNETIC RESONANCE IMAGING; MULTIPLE SCLEROSIS, RELAPSING-REMITTING;

EID: 84879007384     PISSN: 14744422     EISSN: 14744465     Source Type: Journal    
DOI: 10.1016/S1474-4422(13)70108-X     Document Type: Letter

References (6)

1. Hauser SL, Johnston SC Multiple sclerosis drugs: sticker shock. Ann Neurol 2012, 71:A5-A6.
2. Lublin FD, Reingold SC Placebo-controlled clinical trials in multiple sclerosis: ethical considerations. National Multiple Sclerosis Society (USA) Task Force on Placebo-Controlled Clinical Trials in MS. Ann Neurol 2001, 49:677-681.
3. Sormani MP, Bruzzi P MRI lesions as a surrogate for relapses in multiple sclerosis: a meta-analysis of randomised trials. Lancet Neurol 2013, published online June 3. http://dx.doi.org/10.1016/S1474-4422(13)70103-0.
4. Sormani MP, Bonzano L, Roccatagliata L, Cutter GR, Mancardi GL, Bruzzi P Magnetic resonance imaging as a potential surrogate for relapses in multiple sclerosis: a meta-analytic approach. Ann Neurol 2009, 65:268-275.
5. Petkau J, Reingold SC, Held U, et al. Magnetic resonance imaging as a surrogate outcome for multiple sclerosis relapses. Mult Scler 2008, 14:770-778.
6. Fisher E, Lee JC, Nakamura K, Rudick RA Gray matter atrophy in multiple sclerosis: a longitudinal study. Ann Neurol 2008, 64:255-265.